Faculty

Sascha Dublin

Affiliate Professor, Epidemiology

206-287-2870

Education

PhD Epidemiology, University of Washington, 1999
MD University of Washington, 2001

Contact

206-287-2870

Kaiser Permanente Washington Health Research Institute
1730 Minor Avenue, Suite 1600
Seattle, WA 98101

Research Interests

Dr. Dublin’s research interests include pharmacoepidemiology, pregnancy outcomes and perinatal epidemiology; aging; and cardiovascular epidemiology. Her work uses real-world health care data from Group Health and many other sources to better understand the safety and effectiveness of medications and other medical interventions.  She often focuses on the impact of interventions in vulnerable populations, particularly pregnant women and older adults. She also has interest and expertise in using novel statistical and epidemiologic methods to answer real-world questions, such as the use of two-phase study designs to reduce bias and Natural Language Processing  to extract information from electronic medical records (EMRs).  She is the Group Health site Principal Investigator for the Medication Exposures in Pregnancy Risk Evaluation Program (MEPREP), a multisite collaboration that has developed data sets including 1.2 million pregnancies across 11 health plans to examine medication safety in pregnant women.

Recent Publications (PubMed)

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.
(2026 Aug 12)
Eur Urol
Saad F, Shore N, Vjaters E, Olmos D, Littleton N, Testa I, Mo M, Verholen F, Srinivasan S, Haresh KP

Bioinspired pullulan-based adhesive coacervate films for targeted buccal delivery of peptides.
(2026 Oct 1)
Carbohydr Polym 389(): 125612
Sacramento MMA, Ezazi NZ, Pantazoglou E, Lund PM, van de Weert M, Zhang Z, Vitorino R, Bahuon F, Berthelsen R, Buckley ST, Untracht GR, Andersen PE, Brayden DJ, Silva AS, Rodrigues JMM, Mano JF, Nielsen LH

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.
(2026 Aug 12)
Lancet
Motzer RJ, McDermott R, Park SH, Burotto M, Iacovelli R, Verzoni E, Suárez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, Velasco G, Valderrama BP, Azad AA, Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JBAG, Yuan SS, Perini RF, Wang D, Heng DYC, Schmidinger M, LITESPARK-011 Investigators

Incidence of systemic physical multimorbidity among people with schizophrenia-spectrum or bipolar-spectrum disorders compared with age-matched and sex-matched individuals in Queensland, Australia: a statewide, hospital cohort study.
(2026 Sep)
Lancet Psychiatry 13(9): 771-782
Halstead S, Warren N, Kisely S, Arnautovska U, Trott M, Correll CU, Ebdrup BRH, Heffernan E, Mohr GHG, McCutcheon RA, Morley KI, O'Donoghue B, Pillinger T, Sara G, Taipale H, Siskind D

A thiol-rich immunomodulatory injectable hydrogel suppresses endometrial fibrosis to restore fertilization.
(2026 Aug 14)
Sci Adv 12(33): eaef5617
Li M, Zhu R, Tian Y, Yu H, Yang L, Boyi Wang L, Zhou P, Li Q, Song R, Wang W

Show complete publication list

In the News